



SWITZERLAND
INNOVATION

新药研发 Drug Discovery

瑞士制造 Made in Switzerland

邀请函 Invitation

根据中国国家主席和瑞士联邦总统于**2016**年达成的创新战略伙伴关系，**瑞士创新园**诚挚邀请您莅临上海诺华园区，出席新药研发大会。

Based on an innovative strategic partnership agreed between the Chinese President and the President of the Swiss Confederation in 2016, **SWITZERLAND INNOVATION** cordially invites you to the Drug Discovery Event at the Novartis Campus in Shanghai.

时间 Time:

2017年12月5日,周二
Tuesday 5th December, 2017
下午2点到6点
14.00 – 18.00

地点 Venue:

诺华集团
上海市浦东新区金科路4218号
Novartis Campus Shanghai,
Jinke Road 4218, Pudong

着装要求 Dress code:

正装
Formal

活动流程 Program Rundown:

14.00 – 14.30 登记 Registration
14.30 – 15.30 主题发言 Key note speeches
15.30 – 16.30 讨论 Panel Discussion
16.30 – 18.00 交流 Networking

期待您的到来。**11月20**日前，敬请赐复。

如欲参加，请向翁女士

电子邮箱: xinyun.weng@eda.admin.ch

发送电子邮件，确认出席。

We look forward to welcoming you and invite you to RSVP before November 20.

Please send the confirmation of your attendance including contact details to Ms. Weng: xinyun.weng@eda.admin.ch

活动简介

从一步步的假设猜想，到凭借结构化、针对性的方法发现更有效的新疗法，**新药研发**如今已取得长足的进步。为纵观大局、研发新药，各公司需要及时了解基因组学、蛋白质组学、结构或数量生物学方面的最新发现。医药行业必须将科学成果转化为新型的创新产品。

在**瑞士创新园**，科学与医药行业之间的跨学科合作密切无间、蓬勃发展，进而揭开直击精准药物的关键和途径，推动新药研发进入新时代。瑞士创新园携手**瑞士驻华大使馆瑞士贸易与投资处**，致力于推动瑞士成为研发创新之国。罗氏、诺华和爱可泰隆（被强生收购）等国际巨头扎根瑞士，并在此设立全球**研究中心**。其他领先的生物技术和制药公司，其中不乏众多美国公司，同时也包括 AC Immune、Alnylam、安进、百健、蓝鸟、复星、绿叶制药、Prothena 或 Tesaro，也纷纷选择瑞士作为研发基地。诺华和罗氏作为瑞士本土巨擘，吸引全球的高科技人才纷至沓来。

演讲嘉宾



Christoph Hock 教授（医学博士）

- 苏黎世大学医学副校长
- 苏黎世大学施利伦校区再生医学院主任
- 临床科学家，协会认证精神病医师，临床试验研究者

Hock 教授是 Neurimmune 的联合创始人和董事会成员。2007 年，这家生物制药公司与百健合作开展有关阿尔茨海默病的领先项目，并研发出靶向治疗阿尔茨海默病神经变性进程的重组人单克隆抗体。



Michael Hennig 教授（博士）

- 在巴塞尔 F. Hoffman - La Roche AG 从事研究管理，具有长达 20 年的新药研发专业经验
- 巴塞尔大学结构生物学客座教授
- 结构生物学家，高级制药新药研发主管
- 企业家，leadXpro AG 联合创始人

Hennig 教授是生物科技公司 leadXpro AG 的首席执行官和董事会主席，该公司位于瑞士创新园 Innovaare。公司致力于依托膜蛋白靶标的新药研发，探寻结构与生物物理方法。重点研究领域涉及瑞士光影（SLS）、瑞士自由电子激光（SwissFEL）及单颗粒冷冻电镜（cryo-EM）等大型研究设备的使用。LeadXpro 的研究活动专注于先导化合物的开发，以便发现遵循新作用机制、更有效的癌症治疗方法和抗生素。

成功案例

InterAx Biotech AG 是苏黎世联邦理工学院与瑞士保罗谢尔研究所（PSI）的衍生企业，研究基于蛋白质、受知识产权保护的生物传感器，结合信号途径的数学建模，力求发现更安全、更有效的候选药物。

一方面，公司针对棘手的药物靶点研发新药；另一方面，由于能够在高成本、高风险的临床试验之前，更准确地预测药物的安全性和疗效，公司还追求先导分子的精准选择。InterAx Biotech 总部位于瑞士创新园 Innovaare，紧邻瑞士保罗谢尔研究所，便于就地合作，尤其是能与生物化学系密切交流，而且可以及时地将补助金支持的研究（如 CTI 项目）与内部研发协调一致。

SunRegen Healthcare AG 是一家锐意进取的生物制药先锋，总部位于瑞士巴塞尔地区，但拥有中国背景。公司是医疗保健加速计划 Baselaunch 的一员，该计划地点位于巴塞尔地区的瑞士创新园。SunRegen 致力于在传统医学的启发下研发新药，治疗神经退行性疾病。

神经退行性疾病现已成为不容忽视的医学问题，目前市场上很少有直击神经退行性疾病根源的药物。SunRegen 已从中药中找到关键的活性成分，可用于治疗神经退行性疾病。SunRegen 已确定合成物 SBC003 的合成路线。该项目当前处于临床前阶段（体内和体外）。合成物 SBC003 表现出有效的神经保护、抗凋亡、神经抢救以及轴索延展的作用。

About the Event:

Drug discovery has come a long way from guess work to a structural and targeted approach to finding new and better remedies. In order to see the big picture and to develop new drugs, companies need to stay up to date about the latest discoveries in genomics, proteomics, structural or quantitative biology. The industry must translate the scientific efforts into a new innovative product.

At **SWITZERLAND INNOVATION**, such interdisciplinary collaborations between science and industry can flourish, thus finding keys and pathways to more precise medicine and bring drug discovery into a new era. Together with the **Swiss Business Hub China**, SWITZERLAND INNOVATION is committed to promote Switzerland as a location for **R&D and innovation**. International corporations such as Roche, Novartis and Actelion (J&J), have their home base and global research centers in Switzerland. Other leading biotech and pharmaceutical companies – many of them from the US – including AC Immune, Alnylam, Amgen, Biogen, Bluebird, Fosun, Luye Pharma, Prothena or Tesaro have chosen Switzerland as an R&D location. Together with Novartis and Roche as the incumbent players, they attract many highly skilled experts from all over the world.


About the Speakers:



Professor Christoph Hock, MD

- Vice-President Medicine, University of Zurich
- Director at the Institute for Regenerative Medicine, University of Zurich Campus Schlieren
- Clinician-scientist, board-certified psychiatrist, clinical trial investigator

Prof. Hock is the co-founder and board member of Neurimmune. The biopharmaceutical company partnered its lead program in Alzheimer's disease with Biogen in 2007 and developed a recombinant human monoclonal antibody targeting the neurodegenerative process in Alzheimer's disease.



Professor Michael Hennig, PhD

- 20 years of drug discovery expertise from research management at F. Hoffmann – La Roche AG Basel
- Guest Professor for structural biology at the University of Basel
- Structural biologist and senior Pharma drug discovery executive
- Entrepreneur, co-founder of leadXpro AG

Prof. Hennig is CEO and Chairman of the Board of the Biotech company leadXpro AG, located at the Switzerland Innovation Park innovaare. The company is committed to structure and biophysical methods based drug discovery on membrane protein targets. Key areas of research include the use of large research facilities such as Swiss Light Source (SLS), Swiss Free Electron Laser (SwissFEL) and single particle cryo Electron Microscopy (cryo-EM). LeadXpro's research activities are focused on the lead discovery for better cancer treatments and antibiotics with new mechanisms of action.


Success Stories

InterAx Biotech AG is a spin-off of the ETH Zurich and the Paul Scherrer Institute (PSI), combining the output of protein-based IP-protected biosensors with the mathematical modelling of signaling pathways to identify safer and better drug candidates.

On the one hand, the company facilitates drug discovery for difficult-to-handle drug targets; on the other, it will help improve the selection of lead molecules thanks to its ability to better predict drug safety and efficacy before costly and risky clinical trials. With its headquarters at Switzerland Innovation Park innovaare, InterAx Biotech benefits from the direct proximity to the Paul Scherrer Institute which allows the spin-off to collaborate locally with the Institute, in particular with the Division of Biology and Chemistry, and to better align the research supported by grants, such as the CTI project, with its internal R&D.

SunRegen Healthcare AG is a pioneering biopharmaceutical company with Chinese background based in Basel Area of Switzerland. The company is part of the healthcare accelerator program Baselaunch, which is based at the Switzerland innovation Park Basel Area. The mission of SunRegen is to develop novel drugs inspired by traditional medicine to treat neurodegenerative diseases.

Neurodegenerative disorders have a high unmet medical need. Currently there are few drugs on the market which target the root cause of neurodegenerative diseases. SunRegen has found a key active ingredient from a Chinese herb for the treatment of neurodegenerative diseases. SunRegen has established a synthetic route of compound SBC003. The current status of the project is preclinical (in vitro and in vivo). The compound SBC003 demonstrates potent neuroprotective, anti-apoptotic, neuro-rescuing, and axon-outgrowth effects.



承办单位：
Organized by:



知识伙伴：
Knowledge Partner:

